Participation in all clinical trials is voluntary and patients may choose to withdraw from any study at any time. Most of our clinical trials are sponsored by the federally-funded National Institutes of Health (NIH) or pharmaceutical and biotechnology companies. ClinicalTrials.Gov lists these and other clinical trials.
All clinical trials have guidelines called “inclusion criteria” which explain who can participate. Our care team can help you identify clinical trials for which you may be eligible, how long you may be in the study, and what to expect during your experience on the study so you can make an informed decision about participating. Your decision to enroll is entirely yours, and you can withdraw at any time if you change your mind.
Below is a listing of our studies that are currently enrolling new patients.
Click on the name of the study to be directed to each study-specific page on clinicaltrials.gov
- Wet AMD (Age Related Macular Degeneration)
- OPTIC Sponsored by Adverum Biotechnologies
ADVM-022 Intravitreal Gene Therapy for Wet AMD (OPTIC)
- ALTISSIMO Sponsored by Graybug Vision
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD (ALTISSIMO)
- PANDA Sponsored by Chengdu Kanghong
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-1)
- MERLIN Sponsored by Novartis
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)
- TENAYA Sponsored by Roche/Genentech
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
- Kodiak Sciences
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
- Regenexbio
RGX-314 Gene Therapy for Neovascular AMD Trial
- LUCERNE Sponsored by Roche/Genentech
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
- ARCHWAY Sponsored by Roche/Genentech
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)
- PORTAL Sponsored by Roche/Genentech
Extension Study for the Port Delivery System With Ranibizumab (Portal)
- DAZZLE Sponsored by Kodiak Sciences
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. (DAZZLE)
- Dry AMD (Age Related Macular Degeneration)
- LIGHTSITE Sponsored by Lumithera
The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura when administered in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD)
- OAKS Sponsored by APELLIS
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
- Gemini Therapeutics
A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD)
- Gyroscope Therapeutics Sponsored by MedSpace
To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
- AIRM Sponsored by Astellas
To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
- GALLEGO Sponsored by Genentech
A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (GALLEGO)
- Boehringer Ingelheim Pharmaceuticals
Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
- Ophthotech
Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- TOGA Sponsored by University of Virginia
Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) (TOGA)
- Lineage/Cellcure
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
- EXPLORE Sponsored by MedSpace (Gyroscope Therapeutics)
First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
- Uveitis
- HUMBOLDT Sponsored by Gilead
Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis (Humboldt)
- META MUST Sponsored by NEI/NIH
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (MERIT)
- LUMINA Sponsored by Santen
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
- MUST Network
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (ADVISE)
- Retinal Vein Occlusion
- Orion Sponsored by Aerie
Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
- RAPTOR Sponsored by Novartis
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)
- Raven Sponsored by Novartis
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)
- Diabetic Macular Edema
- DRCR.net
DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME (DRCR AC)
- RHINE Sponsored by Roche/Genentech
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)
- YOSEMITE Sponsored by Roche/Genentech
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
- KESTREL Sponsored by Novartis
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)
- Pagoda Sponsored by Genentech
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)
- Diabetic Retinopathy
- GUARD Sponsored by Aldeyra
The GUARD Trial – Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
- Retinitis Pigmentosa
- AGTC
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
